| 治疗肥胖症药——利拉鲁肽 |
| |
| 引用本文： | 王宏亮,张珉,张俊钰,钟武.治疗肥胖症药——利拉鲁肽[J].临床药物治疗杂志,2016(1):81-84. |
| |
| 作者姓名： | 王宏亮 张珉 张俊钰 钟武 |
| |
| 作者单位： | 1. 国家食品药品监督管理总局药品审评中心,北京,100038;2. 西藏军区总医院，拉萨，850007; 国家应急防控药物工程技术研究中心，军事医学科学院毒物药物研究所，北京 100850;3. 西藏军区总医院，拉萨，850007;4. 国家应急防控药物工程技术研究中心，军事医学科学院毒物药物研究所，北京 100850 |
| |
| 摘 要： | 利拉鲁肽(liraglutide,商品名SAXENDA)是由丹麦诺和诺德公司研制的用于肥胖治疗的人胰高血糖素样肽-1(GLP-1)类似物。至2014年12月,FDA批准作为治疗慢性肥胖的药物后,2015年1月欧洲药品管理局(EMA)人用医药产品委员会(CHMP)也已建议批准。在长期临床试验表明,利拉鲁肽(3mg)结合饮食和锻炼,能够有效减轻患者体重,同时也显著改善了肥胖相关合并症,是目前唯一的减肥针剂。笔者从利拉鲁肽的基本信息、作用机制、药动学、药效学、临床试验、不良反应及国内研发动态等方面进行评述,希望能给医院临床合理用药提供帮助。
|
| 关 键 词： | 利拉鲁肽 减肥药 胰高血糖素样肽 |
Obesity Drug - Liraglutide |
| |
| Abstract: | New formulation of liraglutide (brand name Saxenda) is a glucagon-like peptide-1 (GLP-1) analogue developed by Novo Nordisk for the treatment of obesity.UntilDecember 2014, the FDA has approvedSaxenda as a treatment option for chronic weight management in addition to a reduced-calorie diet and physical activity. In January 2015 the Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) adopted a positive opinion for the use of Saxenda for the treatment of obesity. In long-term clinical trials the data showed that liraglutide (3mg) injection can not only effectively help reduce patients' weight with diet and exercise, but also significantly reduce obesity-related complications. This article reviewed the development process, mechanism, pharmacokinetics, pharmacodynamics, clinical trials, adverse reactions and domestic research and development trends of liraglutide. |
| |
| Keywords: | liraglutide obesity drug glucagon-like peptide-1(GLP-1) |
| 本文献已被 万方数据 等数据库收录！ |
|
